Navigation Links
Nutra Pharma Engages Marketing Firm for the Branding and Channel Development of Nyloxin™
Date:3/14/2012

CORAL SPRINGS, Fla., March 14, 2012 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that has developed treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged LWR Partners, an outside branding and marketing firm to aid in the promotion, branding and distribution of Nyloxin™.

"We are excited to be working with LWR Partners to begin our first real marketing efforts for Nyloxin," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "While the Nyloxin products have been available for over a year, sales have been slow as the Company has depended on third-party sales and distributors to get the word out. We are now starting a campaign to have a unified brand strategy and appropriate marketing in our attempt to move sales up consistently both in the United States and abroad," he concluded.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.  Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

"The Nyloxin products represent a wonderful marketing opportunity," commented James Warble, CEO of LWR Partners. "These are pain-relievers and anti-inflammatory drugs that have provided great results with almost no risk of side effects. The only thing missing is a branding and marketing strategy to let the world know about the power of these products," he continued. "LWR will begin an aggressive campaign of digital marketing that includes audio, video, social media, internet banners and sales through more than 10,000 affiliated websites. This will allow the opportunity for sustainable sales growth while building a uniform branding strategy for the products," he concluded.

LWR Partners / "Brands To Market"™ are a select team of best-in-class experts in branding, advertising and media deployment, with a passion for entrepreneurial brand stewardship that knows how to maximize the value of a company's  brand. As a next generation Digital Media Deployment Provider, LWR connects brands to customers through a suite of digital products that includes SMS Mobile, Email, Social Media, Online Video, Web Advertising and Point of Decision media. LWR Partners have created and guided traditional brands like The Die Hard Battery, Taster's Choice Coffee, Jimmy Dean Sausage and currently works with ABA Basketball, The "Seeds of Freedom" Foundation, Commerce Science Corporation and many new top quality Brands. The company is headquartered in Boca Raton, Florida with offices in Atlanta, Nashville, Scottsdale, Austin, Salt Lake City, Scranton, PA and Princeton, NJ

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The engagement of LWR Partners should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutra Pharma Letter to Shareholders
2. Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry
3. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
4. Ajinomoto Co., Inc.s Twofold Nutraceutical Solution Targets Weight Management and Sleep Quality Improvement
5. Nutrastar Announces Adoption of Share Repurchase Program
6. Nutrastar Announces Second Quarter 2011 Financial Results
7. IMD Companies Announces Acquisition of Nutraceutical Company
8. Nutrastar to Present at the Upcoming 2011 Global Hunter Securities Conference
9. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
10. Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details
11. Nutrastar Distribution Spreads into Anhui Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... Genprex, Inc. , a privately held, clinical-stage biopharmaceutical company developing immunogene ... Chief Operating Officer, is scheduled to present a corporate overview at ... Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 ... ... Future Leaders in Biotech Industry – Friday, April 7, 2017 at ...
(Date:3/24/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 ... of cell therapy manufacturing and focuses both on contract manufacturers ... are anticipated to emerge as viable alternatives to conventional treatment ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
(Date:3/28/2017)... GA (PRWEB) , ... March 28, 2017 , ... With ... to Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville ... location since 2016. The new office allows opportunity for transition of Patten Seed operations ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to ... missing teeth can now have them placed by Dr. Manju Kejriwal, with or without ... Beam technology to increase the accuracy of each dental implant placement. The i-CAT CBCT ...
Breaking Medicine News(10 mins):